Meag Munich Ergo’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.01M | Hold |
65,058
| – | – | 0.09% | 117 |
|
|
2025
Q1 | $3.97M | Sell |
65,058
-126,237
| -66% | -$7.36M | 0.12% | 96 |
|
|
2024
Q4 | $10.7M | Sell |
191,295
-61,128
| -24% | -$3.42M | 0.34% | 60 |
|
|
2024
Q3 | $13.1M | Buy |
252,423
+194,981
| +339% | +$9.15M | 0.41% | 59 |
|
|
2024
Q2 | $2.39M | Buy |
57,442
+33,586
| +141% | +$1.5M | 0.08% | 104 |
|
|
2024
Q1 | $1.29M | Hold |
23,856
| – | – | 0.05% | 125 |
|
|
2023
Q4 | $1.22M | Hold |
23,856
| – | – | 0.05% | 125 |
|
|
2023
Q3 | $1.38M | Sell |
23,856
-11,745
| -33% | -$720K | 0.06% | 119 |
|
|
2023
Q2 | $2.28M | Buy |
35,601
+21,065
| +145% | +$1.41M | 0.1% | 108 |
|
|
2023
Q1 | $1.01M | Sell |
14,536
-14,704
| -50% | -$1.04M | 0.05% | 126 |
|
|
2022
Q4 | $2.1M | Hold |
29,240
| – | – | 0.11% | 109 |
|
|
2022
Q3 | $2.08M | Sell |
29,240
-86,694
| -75% | -$6.29M | 0.13% | 105 |
|
|
2022
Q2 | $8.93M | Buy |
115,934
+104,915
| +952% | +$7.99M | 0.53% | 43 |
|
|
2022
Q1 | $815K | Buy |
11,019
+5,619
| +104% | +$377K | 0.06% | 147 |
|
|
2021
Q4 | $339K | Hold |
5,400
| – | – | 0.02% | 156 |
|
|
2021
Q3 | $320K | Sell |
5,400
-61,856
| -92% | -$4.07M | 0.06% | 170 |
|
|
2021
Q2 | $4.49M | Sell |
67,256
-2,811
| -4% | -$183K | 0.43% | 71 |
|
|
2021
Q1 | $4.42M | Buy |
70,067
+64,667
| +1,198% | +$4.02M | 0.44% | 56 |
|
|
2020
Q4 | $334K | Hold |
5,400
| – | – | 0.08% | 170 |
|
|
2020
Q3 | $326K | Sell |
5,400
-4,234
| -44% | -$255K | 0.06% | 182 |
|
|
2020
Q2 | $566K | Buy |
9,634
+2,000
| +26% | +$120K | 0.11% | 156 |
|
|
2020
Q1 | $426K | Sell |
7,634
-47,937
| -86% | -$2.93M | 0.1% | 131 |
|
|
2019
Q4 | $3.54M | Sell |
55,571
-68,111
| -55% | -$3.9M | 0.38% | 67 |
|
|
2019
Q3 | $6.18M | Buy |
123,682
+51,608
| +72% | +$2.43M | 0.32% | 78 |
|
|
2019
Q2 | $3.26M | Buy |
72,074
+10,415
| +17% | +$485K | 0.25% | 95 |
|
|
2019
Q1 | $2.95M | Sell |
61,659
-180,124
| -74% | -$8.97M | 0.24% | 94 |
|
|
2018
Q4 | $12.2M | Buy |
241,783
+68,557
| +40% | +$3.68M | 1.5% | 11 |
|
|
2018
Q3 | $10.7M | Buy |
173,226
+46,837
| +37% | +$2.78M | 0.63% | 39 |
|
|
2018
Q2 | $7.05M | Buy |
126,389
+488
| +0.4% | +$26.4K | 0.44% | 71 |
|
|
2018
Q1 | $7.84M | Sell |
125,901
-42,320
| -25% | -$2.72M | 0.32% | 96 |
|
|
2017
Q4 | $10.5M | Buy |
168,221
+118,545
| +239% | +$7.41M | 0.4% | 70 |
|
|
2017
Q3 | $3.14M | Sell |
49,676
-63,753
| -56% | -$3.72M | 0.13% | 174 |
|
|
2017
Q2 | $6.32M | Buy |
+113,429
| New | +$6.17M | 0.28% | 118 |
|
|
2016
Q3 | – | Sell |
-94,882
| Closed | -$6.97M | – | 258 |
|
|
2016
Q2 | $6.97M | Sell |
94,882
-66,854
| -41% | -$4.72M | 0.63% | 58 |
|
|
2016
Q1 | $10.3M | Buy |
161,736
+50,269
| +45% | +$3.17M | 0.53% | 57 |
|
|
2015
Q4 | $7.8M | Buy |
+111,467
| New | +$7.37M | 0.39% | 85 |
|
|
2015
Q2 | – | Sell |
-52,333
| Closed | -$3.4M | – | 203 |
|
|
2015
Q1 | $3.4M | Buy |
+52,333
| New | +$3.28M | 0.16% | 140 |
|
|
2014
Q1 | – | Sell |
-151,163
| Closed | -$8.07M | – | 205 |
|
|
2013
Q4 | $8.07M | Sell |
151,163
-76,974
| -34% | -$3.92M | 0.47% | 70 |
|
|
2013
Q3 | $10.5M | Buy |
228,137
+69,778
| +44% | +$3.06M | 0.74% | 49 |
|
|
2013
Q2 | $7.18M | Buy |
+158,359
| New | +$6.88M | 0.54% | 64 |
|
Other funds holding BMY
Meag Munich Ergo's BMY Position: Q2 2025 in Review
Meag Munich Ergo held its Bristol-Myers Squibb (BMY) position steady in Q2 2025 at 65,058 shares worth $3.01M. The position accounts for 0.09% of the portfolio, ranked #117.
Meag Munich Ergo first reported a position in BMY in Q2 2013 and has held it in 40 quarters since. The position peaked at $13.1M in Q3 2024. 2,292 funds tracked by Wall St. Rank hold BMY as of Q2 2025.
- Meag Munich Ergo held 65,058 shares of Bristol-Myers Squibb worth $3.01M as of Q2 2025.
- Meag Munich Ergo left its Bristol-Myers Squibb share count unchanged in Q2 2025.
- Bristol-Myers Squibb made up 0.09% of Meag Munich Ergo's portfolio in Q2 2025, its #117 holding.
- Meag Munich Ergo first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 40 quarters since.
- Meag Munich Ergo's Bristol-Myers Squibb position peaked at $13.1M in Q3 2024.
- 2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.
Based on Meag Munich Ergo's 13F filing for Q2 2025, filed 16 Jul 2025.